Published in conjunction with the 2016 ASCO Annual Meeting
Genotyping in patients with advanced NSCLC may identify mutations amenable to targeted therapy. We identified in a 2010-2014 community series a 60% testing rate for EGFR/ALK among stage IV patients (Gutierrez ASCO 2015; e19113). 2014 guidelines added 5 additional targets for testing.
Authors: Martin Gutierrez, Kelly Choi, Richard Burnham Lanman, Stan M Skrzypczak, Ruth Pe Benito, Victoria DeVincenzo, Yvonne Owusu-Sarpong, Courtney Anderson, Dhakshila Paramanathan, Kathyrn Tanenbaum, Matthew Love, Eric V Schultz, Andrew Pecora, Stuart L. Goldberg; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; COTA, New York, NY; Guardant Health Inc., Redwood City, CA